Narcolepsy

17 trials 4 recruiting MedDRA PT
17 Registered trials
4 Recruiting
6 Unique sponsors
4 Unique IMPs
17 Commercial trials
Drug classes (ATC)
— ATC code not specified 17
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Phase III: 4 Phase II/III: 2 Phase II: 4 Phase I (Other): 7

Filter these 17 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 17 trials

Phase III

4 trials
  • Alkermes Inc. Commercial
    ALKS 2680
    2025-523911-13-00 4 countries n=56
    Pending
  • Jazz Pharmaceuticals PLC Commercial
    SODIUM OXYBATE, CALCIUM OXYBATE, MAGNESIUM OXYBATE, POTASSIUM OXYBATE
    2023-504892-25-00 5 countries 2024 n=37
    Ended
  • Takeda Development Center Americas Inc. Commercial
    N-{(2S,3R)-4,4-DIFLUORO-1-(2-HYDROXY-2-METHYLPROPANOYL)-2-[(2,3',5'-TRIFLUORO[1,1'-BIPHENYL]-3-YL)METHYL]PYRROLIDIN-3-YL}ETHANESULFONAMIDE
    2023-508465-32-00 6 countries 2024 n=85 Orphan
    Ended
  • Takeda Development Center Americas Inc. Commercial
    N-{(2S,3R)-4,4-DIFLUORO-1-(2-HYDROXY-2-METHYLPROPANOYL)-2-[(2,3',5'-TRIFLUORO[1,1'-BIPHENYL]-3-YL)METHYL]PYRROLIDIN-3-YL}ETHANESULFONAMIDE
    2024-511998-30-00 11 countries 2024 n=80 Orphan
    Ended

Phase II/III

2 trials
  • Alkermes Inc. Commercial
    ALKS 2680
    2024-519822-18-00 6 countries 2025 n=141
    Recruiting
  • Takeda Development Center Americas Inc. Commercial
    N-{(2S,3R)-4,4-DIFLUORO-1-(2-HYDROXY-2-METHYLPROPANOYL)-2-[(2,3',5'-TRIFLUORO[1,1'-BIPHENYL]-3-YL)METHYL]PYRROLIDIN-3-YL}ETHANESULFONAMIDE
    2023-508462-15-00 11 countries 2023 n=304 Orphan
    Ended

Phase II

4 trials
  • Alkermes Inc. Commercial
    ALKS 2680
    2024-515452-20-00 6 countries 2025 n=124
    Ended
  • Centessa Pharmaceuticals UK Limited Commercial
    ORX750
    2024-518929-15-00 3 countries 2025 n=34
    Recruiting
  • Centessa Pharmaceuticals UK Limited Commercial
    ORX750
    2025-522987-34-00 3 countries 2026 n=55
    Recruiting
  • Takeda Development Center Americas Inc. Commercial
    IMP not specified
    2024-517711-70-01 3 countries 2025 n=43
    Recruiting

Phase I (Other)

7 trials
  • Bioprojet Pharma Commercial
    IMP not specified
    2023-503945-78-00 1 country 2023 n=75
    Ended
  • Bioprojet Pharma Commercial
    IMP not specified
    2023-505769-98-00 1 country 2023 n=16
    Ended
  • Bioprojet Pharma Commercial
    IMP not specified
    2023-507316-12-00 1 country 2023 n=104
    Ended
  • Bioprojet Pharma Commercial
    IMP not specified
    2024-513383-26-00 1 country 2024 n=16
    Ended
  • Bioprojet Pharma Commercial
    IMP not specified
    2025-520980-41-00 1 country 2025 n=16
    Ended
  • Merck Sharp & Dohme LLC Commercial
    IMP not specified
    2023-504954-37-00 1 country 2023 n=64
    Ended
  • Takeda Development Center Americas Inc. Commercial
    N-{(2S,3R)-4,4-DIFLUORO-1-(2-HYDROXY-2-METHYLPROPANOYL)-2-[(2,3',5'-TRIFLUORO[1,1'-BIPHENYL]-3-YL)METHYL]PYRROLIDIN-3-YL}ETHANESULFONAMIDE
    2025-522034-31-00 1 country 2026 n=16 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Takeda Development Center Americas Inc. Commercial 5 Phase II/III, Phase I (Other), Phase II, Phase III 1
Bioprojet Pharma Commercial 5 Phase I (Other) 0
Alkermes Inc. Commercial 3 Phase II/III, Phase II, Phase III 1
Centessa Pharmaceuticals UK Limited Commercial 2 Phase II 2
Merck Sharp & Dohme LLC Commercial 1 Phase I (Other) 0
Jazz Pharmaceuticals PLC Commercial 1 Phase III 0
New trials by year
2023
5
2024
4
2025
5
2026
2
← All indication landscapes